A new CFTR modulator treatment called Alyftrek has been approved for people with CF ages 6 and older who have CFTR mutations ...

It's also more powerful than Trikafta, and has a significantly lower ... That's enormously important, considering the side effects and addictive potential of opioids. Vertex is already preparing ...

Trikafta is the most important of this group ... With 88% of healthcare providers concerned about the risks of side effects of current pain medications and 78% concerned about the risk of opioid ...

Experts say patients should adjust dosage, try prescribed and over-the-counter drugs to help with symptom management and ...

There’s a balance required to manage both the symptoms of myelofibrosis through treatment and the side effects caused by the ...

According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

In a new report this week, the FDA highlighted several serious adverse events and deaths associated with the drug Librela.